Expert updates on current CF pipeline

Matthias Griese, head of the cystic fibrosis center at the children's hospital of the University of Munich, noted the current key candidates for treating CF in development since 2005 in a presentation at the European Respiratory Society conference in Berlin, Germany.

As part of a talk sponsored by Italy's Chiesi Foundation, Dr Griese offered an update on the progress of the following drugs:

- Bramitob (inhaled tobramycin), Chiesi's first CF product, approved in most of Europe this year;